

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU578404695US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: January 7, 2003

Signature

(Ronnie Webb)

Docket No.: HO-P02046US1
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:
Marie-Claude Gingras, et al.

Application No.: 10/021,509

Filed: December 7, 2001

For: TREM-1 SPLICE VARIANT FOR USE AND
MODIFYING IMMUNE RESPONSES

Group Art Unit: N/A

Examiner: Not Yet Assigned

RECEIVED
JAN 09 2003
TECH CENTER 1600/2900
pff6

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information

25248511.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02046US1.

Dated: January 7, 2003

Respectfully submitted,

By 
Melissa W. Acosta
Registration No.: 45,872
FULBRIGHT & JAWORSKI L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-5151
(713) 651-5246 (Fax)



Approved for use through 10/31/2003. PTO/BB 08A (10-01)
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known Application Number 10/021,509 Filing Date December 7, 2001 First Named Inventor Marie-Claude Gingras Art Unit N/A Examiner Name Not Yet Assigned Attorney Docket Number HO-PO2046US1	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	6,087,331-	07-11-2000	Newman et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	BA	JP-WO99/18126-	04/15/1999	Ono Pharmaceutical Co., Ltd.	
	BB	EP-EP 1 022 286-A1	07/26/2000	Ono Pharmaceutical Co., Ltd.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	Dietrich, Jes, et al.; Cutting Edge: Signal-Regulatory Protein $\beta 1$ Is a DAP12-Associated Activating Receptor Expressed in Myeloid Cells; The Journal of Immunology, 2000, 164:9-12			
	CB	Lanier, Lewis L., et al.; Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells; Nature, Vol. 391, pp 703 - 707, February 12, 1998			
	CC	Bakker, Alexander B., et al.; Myeloid DAP1-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells; Proc. Natl. Acad. Sci. USA, Vol. 96, pp 9792 - 9796, August 1999 (Immunology)			
	CD	Lanier, Lewis L.; NK Cell Receptors; Annu. Rev. Immunol. 1998, 16:359-93			
	CE	Tapping, Richard L., et al.; Soluble CD14-Mediated Cellular Responses to Lipopolysaccharide; Chem Immunol. Basel, Karger, 2000, Vol 74, pp 108 - 121			
	CF	Campbell, Kerry S., et al.; DAP12: a key accessory protein for relaying signals by Natural Killer cell receptors; The International Journal of Biochemistry & Cell Biology 31 (1999) 631 - 636			
	CG	Bouchon, Axel, et al.; Cutting Edge: Inflammatory Responses Can Be Triggered by TREM-1, a Novel Receptor Expressed on Neutrophils and Monocytes; The Journal of Immunology, 2000, 164: 4991 - 4995			
	CH	Lanier, Lewis L., et al.; Association of DAP12 with Activating CD94/NKG2C NK Cell Receptors; Immunity, Vol. 8, pp 693 - 701, June 1998			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Michail Belyavskiy/ (02/03/2009)	Date Considered	
--------------------	-----------------------------------	-----------------	--

#25248520 1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/